NCT03932461

Brief Summary

Multicenter randomized controlled trial including patients with fecal or diffuse peritonitis to either vacuum assisted closure or relaparotomy "on-demand".

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
340

participants targeted

Target at P75+ for not_applicable

Timeline
16mo left

Started Jun 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Jun 2020Sep 2027

First Submitted

Initial submission to the registry

April 25, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 30, 2019

Completed
1.1 years until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Expected
Last Updated

November 7, 2023

Status Verified

November 1, 2023

Enrollment Period

4.3 years

First QC Date

April 25, 2019

Last Update Submit

November 6, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Primary endpoint is to compare peritonitis related complications and Comprehensive Complication Index (CCI) between NPWT treatment (VAC) and conventional treatment (ROD) at 30, 90 days and 1 year.

    Disease-Related Major Morbidity Needing Readmission and Conservative Treatment but Not Surgery * Fistula * Wound dehiscence/incisional hernia with obstruction * Abscess needing percutaneous drainage * Renal failure * Myocardial infarction * Gastric or duodenal bleeding * Respiratory failure * Urosepsis Disease-Related Major Morbidity Needing Surgical Intervention During First Admission or Readmission * Incisional hernia * Bowel obstruction or herniation due to intra-abdominal adhesions * Burst abdomen * Abdominal compartment syndrome * Fistula * Intra-abdominal bleeding * Intra-abdominal hematoma needing surgical evacuation * Perforation of visceral organ confirmed at surgery * Anastomotic leakage * Ischemia or necrosis of a visceral organ * Enterostomy dysfunction due to prolapse, stenosis, or retraction * Gastric or duodenal ulcer bleeding needing intervention of any type

    1 year

Secondary Outcomes (4)

  • Mortality at 30, 90 days and 1 year

    1 year

  • Quality of life after treatment

    3 and 12 months

  • Ventral hernia rate

    3 and 12 months

  • Hospital care utility within three months after index surgery

    Up to 12 weeks

Other Outcomes (2)

  • Microdialysis

    First 4 days afte index laparatomy

  • Inscional hernia

    3 years

Study Arms (2)

Vacuum assisted closure

ACTIVE COMPARATOR

The VAC® Abdominal Dressing System (KCI Vacuum Assisted Closure, San Antonio, TX, USA) will be used. Intestines, including lateral aspects, are covered by the visceral protective layer. The first layer of foam is placed in the laparostoma on the visceral protective layer and must extend below the fascia at a distance of 5 cm from the facial opening. Above this, a minimum of one piece of foam is folded and placed in the laparostoma. Finally, the laparostoma will be covered by the occlusive drape. A circular opening of approximately 5 cm in diameter will be created in the drape where the connection tubes to the vacuum pump will be placed. Simultaneously while applying the negative pressure of 125 mmHg, the wound edges are approximated manually towards the midline. Each dressing change must be performed in the operation theatre with the patient in general anesthesia and muscle relaxation.

Procedure: Vacuum assisted closure

Relaparotomy "on-demand"

ACTIVE COMPARATOR

The Isreaelsson principle includes a running suture of the fascia with a distance of 5 mm between the stitches of 5 mm and the distance to the facial edge of 5-10 mm. Monofilament PDS 2-0 or equivalent is used. The suturing is started cranially and caudally, and the sutures are tied with self-locking knots. Four times as much suture material as the length of the wound must be used. The peritoneal fluid must be cultured at closure. The treating surgeon decides to perform a ROD and should be guided by the patient's general condition, gastrointestinal function, renal function, and inflammatory parameters at daily rounds.

Procedure: Relaparotomy "on demand"

Interventions

The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.

Also known as: VAC® Abdominal Dressing System, KCI, (San Antonio, TX)
Vacuum assisted closure

Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.

Relaparotomy "on-demand"

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients eligible for enrolment are 18+ years of age and are scheduled for acute laparotomy due to suspected peritonitis originating from perforation of the small bowel, colon, or rectum. To be included, purulent, enteric, or fecal contamination in a minimum of 2 out of 4 quadrants must be confirmed.

You may not qualify if:

  • Diffuse peritonitis originating from a different focus than the small intestine, colon or rectum
  • Diffuse peritonitis originating from a perforation on the stomach, duodenum, gallbladder, appendix, necrotizing pancreatitis, salpingitis, or peritoneal dialysis
  • Primary peritonitis
  • Immunocompromised (ongoing chemotherapy or prednisolone \>20 mg/day)
  • Chronic parenchymal liver disease
  • Pregnancy
  • Patients with end-stage disease
  • Laparoscopic surgery (not converted to laparotomy)
  • Acute occlusion of superior mesenteric artery
  • Peritoneal carcinomatosis
  • Abdominal trauma
  • Lack of consent from the surgical equipoise
  • Local peritonitis confined to 1 quadrant only

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Odense University Hospital

Odense, Fyn, 5000, Denmark

RECRUITING

Related Publications (1)

  • Rajabaleyan P, Michelsen J, Tange Holst U, Moller S, Toft P, Luxhoi J, Buyukuslu M, Bohm AM, Borly L, Sandblom G, Kobborg M, Aagaard Poulsen K, Schou Love U, Ovesen S, Grant Solling C, Morch Sondergaard B, Lund Lomholt M, Ritz Moller D, Qvist N, Bremholm Ellebaek M; VACOR study group. Vacuum-assisted closure versus on-demand relaparotomy in patients with secondary peritonitis-the VACOR trial: protocol for a randomised controlled trial. World J Emerg Surg. 2022 May 26;17(1):25. doi: 10.1186/s13017-022-00427-x.

MeSH Terms

Conditions

Peritonitis

Interventions

Negative-Pressure Wound Therapy

Condition Hierarchy (Ancestors)

Intraabdominal InfectionsInfectionsPeritoneal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

DrainageTherapeuticsSurgical Procedures, OperativeWound Closure Techniques

Study Officials

  • Niels Qvist, Professor

    Surgical Department A, Odense University Hospital, Denmark

    STUDY DIRECTOR
  • Uffe Tange Holst, M.D.

    Surgical Department A, Odense University Hospital, Denmark

    STUDY CHAIR
  • Jens Michelsen, M.D.

    Anesthesiology department V, Odense University Hospital, Denmark

    STUDY CHAIR
  • Palle Toft, Professor

    Anesthesiology department V, Odense University Hospital, Denmark

    STUDY CHAIR

Central Study Contacts

Pooya Rajabaleyan, M.D.

CONTACT

Mark Ellebæk, M.D., Ph.d.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Multicentre randomized non-blinded clinical trial comprising of \> 4 centres. In total there will be included 320 patients.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

April 25, 2019

First Posted

April 30, 2019

Study Start

June 1, 2020

Primary Completion

September 1, 2024

Study Completion (Estimated)

September 1, 2027

Last Updated

November 7, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations